查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1197119

医疗保健纳米技术（纳米医学）市场——增长、趋势、COVID-19 的影响和预测 (2023-2028)

Healthcare Nanotechnology (Nanomedicine) Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 130 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

在预测期内，医疗保健纳米技术（纳米医学）市场预计将以 11.9% 左右的复合年增长率增长。

纳米技术的使用为开发预防、诊断和治疗 COVID-19 和其他病毒感染的新策略提供了新的机会。 随着纳米材料的开发，如消毒剂、个人防护设备、诊断系统和用于治疗和疫苗开发的纳米载体系统，COVID-19 管理得以实现。 根据 Estefania V. R. Campos 等人于 2020 年发表在 Journal of Nanobiotechnology 上的研究论文，硫醇修饰的探针在金纳米粒子表面功能化并与靶标杂交，以防止纳米粒子因盐而聚集。结果，它可以防止颜色变化。 该解决方案可轻鬆适用于 COVID-19 的诊断。

医疗保健纳米技术（纳米医学）市场受多种因素驱动。

纳米医学可以帮助改善人类健康，并为多种危及生命的疾病提供解决方案，包括癌症、帕金森氏症、阿尔茨海默氏症、糖尿病、骨科疾病以及与血液、肺和循环系统相关的疾病。它提供 据国际阿尔茨海默氏症协会称，到 2020 年，全球将有大约 5000 万痴呆症患者。 这个数字预计每 20 年翻一番，到 2030 年达到 8200 万，到 2050 年达到 1.52 亿。 因此，预计痴呆症的高负担将推动在疾病管理中对基于纳米药物的有效疗法的需求，从而推动市场增长。

此外，市场参与者正在努力频繁发布产品以增加他们的影响力。 例如，2020 年 10 月，Medtronic PLC 推出了新的 Adaptix Interbody System，这是一种采用 Titan nanoLOCK 表面技术的导航钛脊柱植入物。

然而，与传统药物相比，纳米颗粒辅助药物的严格监管问题和高成本阻碍了市场增长。

医疗保健纳米技术市场趋势

预计肿瘤疾病领域在预测期内将呈现更好的增长

纳米医学是一种很有前途的癌症治疗模式。 可以利用这一不断发展的医学研究领域来发现针对包括癌症在内的多种疾病的更加个性化的治疗方法。 在全球范围内，癌症的患病率正在增加。 例如，根据GLOBOCAN，2020，预计2020年全球癌症患者人数将增加到1930万，癌症死亡人数将增加到1000万。

在肿瘤学领域，纳米医学为现有的癌症治疗和诊断方法带来了充满希望的变革。 基于纳米的癌症治疗和诊断的采用取得了显着进展，目前正在进行一些新的发展。

根据 2021 年 7 月发表的研究论文“用于纳米医学和癌症的纳米材料开发的最新进展”，具有不同形状、尺寸和成分的各种工程纳米材料可用于各种生物医学应用。已开发出一个纳米平台. 纳米材料和设备也被广泛用于开发即时和高灵敏度的癌症检测方法。 因此，用于癌症检测的纳米医学的进步正在推动市场增长。

此外，使用纳米医学技术的抗癌药物的频繁上市也在显着推动市场。 2019 年 4 月，处于临床阶段的纳米药物公司 Nanobiotix 宣布了结晶氧化铪 (HfO2) 纳米颗粒，该纳米颗粒设计用于在晚期软组织肉瘤患者的首次标准放疗前直接注射到肿瘤中。其水性悬浮液“Hensify ( NBTXR3)”。

在 Ye Zhang 等人发表于 2019 年血液学与肿瘤学杂誌的研究论文中，纪念斯隆-凯特琳癌症中心和康奈尔大学的研究人员开发了二氧化硅杂化纳米颗粒 (Cdots)。 这些与 124 I 标记的环-[Arg-Gly-Asp-Tyr] (cRGDY) □缀合的纳米颗粒可以选择性地结合整合素，因此可以用作肿瘤细胞探针。

预计北美市场份额最大

市场增长主要由与慢性病和急性病的早期诊断、预防性干预和预防相关的技术进步和应用推动，预计这些将推动美国的市场增长。

例如，根据美国疾病控制与预防中心的数据，到 2021 年，心脏病将导緻美国四分之一的死亡。 冠心病是美国心血管疾病死亡的主要原因，有 360,900 人死亡，其次是中风 (805,000 人)。 这种高负担可能会导致对特定治疗性纳米载体、纳米结构支架和组织再生植入物的高需求。

此外，该国正在进行多项与基于纳米技术的药物和诊断相关的研发活动，这可能是市场增长的推动力。 例如，2020 年 1 月，斯坦福大学的研究人员开发了一种纳米颗粒涂层药物，该药物通过减少动脉中的斑块积聚而不会引起有害的副作用，从而限制小鼠动脉粥样硬化的进展。

此外，一些主要的国内市场参与者正在开发新产品和技术以与现有产品竞争，而另一些则正在开发其他符合市场趋势的公司。我们正在进行收购和合作。 2020年，Nanox Imaging 和 SPI Medical 达成协议，在墨西哥销售和引进 Nanox 的新型 X 射线设备。 Nanox ARC 使用纳米技术和半导体来取代传统机器中的阴极射线管。

此外，在 COVID-19 大流行期间，人们发现纳米医学在疫苗开发中发挥着重要作用。 该地区的科学家和市场参与者正在进行越来越多的实验研究，以找到能够有效对抗高度传染性 COVID-19 病毒的合适且有前途的疗法。 2020 年 10 月，加拿大政府宣布向 Precision Nanosystems 提供 1820 万美元的资金，用于开发针对 COVID-19 的 RNA 疫苗。 这项投资将支持使用基于脂质的药物输送系统和纳米药物开发具有成本效益的 COVID-19 疫苗。

医疗保健纳米技术市场的竞争对手分析

主要市场参与者正在关注药物生物利用度和药物管理方面的技术进步和改进。 预计 COVID-19 大流行带来的有利增长机会将推动新参与者进入市场。 市场上的主要参与者包括 Sanofi SA、辉瑞公司、Celgene 公司、Luminex 公司、台湾脂质体有限公司。 此外，一些公司正在努力将基于纳米技术的药物和诊断工具推向市场。 例如，2020 年 8 月，Promimic 合作伙伴 Innovasis Inc. 获得美国 FDA 批准推出用于脊柱融合手术的 3D 打印植入物。 此外，这些植入物使用了 Promimic 的 HAnano 表面技术，这是一种在植入装置表面进行的生物活性纳米处理，可增加医疗植入物的分子锚定。

其他福利。

  • Excel 格式的市场预测 (ME) 表
  • 3 个月的分析师支持

内容

第1章介绍

  • 研究假设和市场定义
  • 调查范围

第2章研究方法论

第 3 章执行摘要

第4章市场动态

  • 市场概览
  • 市场驱动力
    • 癌症、遗传病和心血管疾病的患病率增加
    • 诊断程序中纳米级技术的进步
    • 对个性化医疗的偏好不断上升
  • 市场製约因素
    • 成本高
    • 对商业介绍的严格监管
  • 波特的五力分析
    • 新进入者的威胁
    • 买方/消费者议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 竞争公司之间的敌对关係

第 5 章市场细分（基于价值的市场规模：百万美元）

  • 通过申请
    • 给药
    • 生物材料
    • 主动植入
    • 影像诊断
    • 组织再生
  • 按疾病分类
    • 心血管疾病
    • 癌症相关疾病
    • 神经系统疾病
    • 骨科
    • 感染
    • 其他疾病
  • 按地区细分
    • 北美
      • 美国
      • 加拿大
      • 墨西哥
    • 欧洲
      • 法国
      • 德国
      • 英国
      • 意大利
      • 西班牙
      • 其他欧洲地区
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 其他亚太地区
    • 中东
      • 海湾合作委员会
      • 南非
      • 其他中东地区
    • 南美洲
      • 巴西
      • 阿根廷
      • 其他南美洲

第6章竞争格局

  • 公司简介
    • Sanofi SA
    • Bristol-Myers Squibb Company
    • CytImmune Sciences Inc.
    • Johnson & Johnson
    • Luminex Corporation
    • Merck & Co. Inc.
    • Nanobiotix
    • Pfizer Inc.
    • Starpharma Holdings Limited
    • Taiwan Liposome Company Ltd
    • Copernicus Therapeutics Inc.
    • NanoCarrier Co. Ltd
    • Ensysce Biosciences Inc.
    • Ocuphire Pharma Inc.
    • LiPlasome Pharma ApS
    • Nami Therapeutics Corp.
    • Nanospectra Biosciences
    • CytImmune Sciences
    • Genetic Immunity
    • Spago Nanomedical AB

第7章 市场机会与今后动向

简介目录
Product Code: 52957

The healthcare nanotechnology (nanomedicine) market is expected to register a CAGR of nearly 11.9% during the forecast period.

The use of nanotechnology offers new opportunities for the development of novel strategies in terms of prevention, diagnosis, and treatment of COVID-19 and other viral infections. COVID-19 management was done with the development of nano-based materials, such as disinfectants, personal protective equipment, diagnostic systems, and nanocarrier systems, for treatments and vaccine development. According to a research article by Estefania V. R. Campos et al., published in the Journal of Nanobiotechnology in 2020, gold nanoparticles were functionalized with probes modified with thiol on the surface, which hybridize with the target and prevent the aggregation of the nanoparticles by salts and, consequently, the color change. This solution can be easily adapted for the diagnosis of COVID-19.

The healthcare nanotechnology (nanomedicine) market is being driven by various factors, such as the growing prevalence of cancer and genetic and cardiovascular diseases, increasing advancements in nanoscale technologies for diagnostic procedures, and growing preference for personalized medicines.

Nanomedicine helps improve human health and offers solutions for various life-threatening diseases, such as cancer, Parkinson's disease, Alzheimer's disease, diabetes, orthopedic diseases, and diseases related to blood, lungs, and the cardiovascular system. According to Alzheimer's Disease International, globally, there were around 50 million people with dementia in 2020. This number is expected to double every 20 years, reaching 82 million in 2030 and 152 million in 2050. Therefore, the high burden of dementia is expected to increase the demand for effective therapeutics based on nanomedicine in the management of the disease, which is expected to drive market growth.

Moreover, the market players are involved in frequent product launches to enhance their presence. For instance, in October 2020, Medtronic PLC launched its new Adaptix Interbody System, a navigated titanium spinal implant with the Titan nanoLOCK Surface Technology.

However, stringent regulatory issues and the high cost of nanoparticle-assisted medicine relative to its traditional counterparts are hindering the market's growth.

Healthcare Nanotechnology Market Trends

The Oncological Diseases Segment is Expected to Show Better Growth During the Forecast Period

Nanomedicine is a promising mode of cancer treatment. This growing field of medical research can be used to discover better-personalized treatments for a wide range of diseases, including cancer. Globally, the prevalence of cancer is increasing. For instance, according to GLOBOCAN, 2020, the global cancer burden increased to 19.3 million cases and 10 million cancer deaths in 2020.​

In the field of oncology, nanomedicine offers promising transformations from the existing methods of treatments and diagnosis of cancer. The adoption of nano-based cancer therapies and diagnostics witnessed noteworthy progress, and numerous new developments are currently in the pipeline.

According to a research article titled "Recent Advances in Nanomaterials Development for Nanomedicine and Cancer", published in July 2021, a wide range of engineered nanomaterials and nanoplatforms with different shapes, sizes, and compositions has been developed for various biomedical applications. The nano-based materials and devices have also been used extensively to develop point-of-care and highly sensitive methods of cancer detection. Thus, advances in nanomedicine for the detection of cancer are driving the market's growth.

Moreover, the frequent launches of cancer medicines with nanomedicine technology are driving the market significantly. In April 2019, Nanobiotix, a clinical-stage nanomedicine company, obtained the CE approval for its Hensify (NBTXR3), an aqueous suspension of crystalline hafnium oxide (HfO2) nanoparticles designed for injection directly into the tumor before a patient's first standard radiotherapy treatment of advanced soft tissue sarcoma.

According to a research article by Ye Zhang et al., published in the Journal of Hematology & Oncology Journal 2019, researchers at the Memorial Sloan Kettering Cancer Center and Cornell University developed silica-hybrid nanoparticles (C-dots) for PET imaging of patients with metastatic melanoma or malignant brain tumors. These nanoparticles, coupled with 124I-labeled cyclo-[Arg-Gly-Asp-Tyr] (cRGDY) peptides, can selectively bind to integrins and can be used to probe tumor cells.

North America is Expected to Hold the Largest Share of the Market

The major factors attributing to the market's growth are technological advancements, coupled with relevant applications in early disease diagnosis, preventive intervention, and prophylaxis of chronic and acute disorders, which are expected to bolster the market's growth in the United States.

For instance, according to the Centers for Disease Control and Prevention, 2021, heart disease accounted for one in four deaths in the United States. Coronary heart disease is the leading cause of deaths attributable to cardiovascular disease in the United States, causing 360,900 deaths, followed by stroke (805,000). This high burden may lead to the high demand for specific therapeutic nanovectors, nanostructured stents, and implants for tissue regeneration.

Moreover, several R&D activities are ongoing in the country on drugs and diagnostics based on nanotechnology, which may drive market growth. For instance, in January 2020, researchers from Stanford University developed a drug coated with nanoparticles that limits the development of atherosclerosis in mice by reducing plaque buildup in their arteries without causing harmful side effects.

Additionally, a few of the key market players in the country are developing novel products and technologies to compete with the existing products, while others are acquiring and partnering with other companies trending in the market. In 2020, Nano-X Imaging and SPI Medical entered an agreement to distribute and introduce Nanox's novel X-ray systems in Mexico. Nanox ARC uses nanotechnology and semiconductors to replace the cathode ray tubes in traditional machines.

Additionally, during the COVID-19 pandemic, nanomedicine has been found to play a key role in the development of vaccines. Scientists and market players in the region are increasing experimental studies to find suitable and promising therapeutics that may effectively tackle the highly contagious COVID-19 virus. In October 2020, the Canadian government announced the funding of USD 18.2 million to Precision NanoSystems to develop an RNA vaccine for COVID-19. This investment will support the development of a cost-effective COVID-19 vaccine by using lipid-based drug delivery systems and nanomedicine.

Healthcare Nanotechnology Market Competitor Analysis

The major market players are focusing on technological advancements and improvements in drug bioavailability and drug administration. Lucrative growth opportunities due to the COVID-19 pandemic are expected to drive the entry of new players into the market. Some of the major players in the market are Sanofi SA, Pfizer Inc., Celgene Corporation, Luminex Corporation, and Taiwan Liposome Company Ltd. Moreover, several companies are working on launching nanotechnology-based medicines and diagnostic tools. For instance, in August 2020, Promimic's partner, Innovasis Inc., received the US FDA clearance to launch 3D-printed implants used in spinal fusion surgery. In addition, these implants use Promimic's HAnano Surface Technology, a bioactive nano treatment for implant device surfaces that leads to increased molecular anchoring of medical implants.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Prevalence of Cancer and Genetic and Cardiovascular Diseases
    • 4.2.2 Increasing Advancements in Nanoscale Technologies for Diagnostic Procedures
    • 4.2.3 Growing Preference for Personalized Medicines
  • 4.3 Market Restraints
    • 4.3.1 High Costs
    • 4.3.2 Stringent Regulations for Commercial Introduction
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Application
    • 5.1.1 Drug Delivery
    • 5.1.2 Biomaterials
    • 5.1.3 Active Implants
    • 5.1.4 Diagnostic Imaging
    • 5.1.5 Tissue Regeneration
  • 5.2 By Disease
    • 5.2.1 Cardiovascular Diseases
    • 5.2.2 Oncological Diseases
    • 5.2.3 Neurological Diseases
    • 5.2.4 Orthopedic Diseases
    • 5.2.5 Infectious Diseases
    • 5.2.6 Other Diseases
  • 5.3 By Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 France
      • 5.3.2.2 Germany
      • 5.3.2.3 United Kingdom
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Sanofi SA
    • 6.1.2 Bristol-Myers Squibb Company
    • 6.1.3 CytImmune Sciences Inc.
    • 6.1.4 Johnson & Johnson
    • 6.1.5 Luminex Corporation
    • 6.1.6 Merck & Co. Inc.
    • 6.1.7 Nanobiotix
    • 6.1.8 Pfizer Inc.
    • 6.1.9 Starpharma Holdings Limited
    • 6.1.10 Taiwan Liposome Company Ltd
    • 6.1.11 Copernicus Therapeutics Inc.
    • 6.1.12 NanoCarrier Co. Ltd
    • 6.1.13 Ensysce Biosciences Inc.
    • 6.1.14 Ocuphire Pharma Inc.
    • 6.1.15 LiPlasome Pharma ApS
    • 6.1.16 Nami Therapeutics Corp.
    • 6.1.17 Nanospectra Biosciences
    • 6.1.18 CytImmune Sciences
    • 6.1.19 Genetic Immunity
    • 6.1.20 Spago Nanomedical AB

7 MARKET OPPORTUNITIES AND FUTURE TRENDS